LexBlog IP

DECEMBER 2, 2022

announced its intent to acquire the global biosimilars business of its long-term partner Viatris, Inc. billion comes from a Sustainability Linked Loan (SLL), making it the largest SLL to pharmaceutical and biomanufacturing companies in the Asia-Pacific region. As we previously reported , Biocon Biologics Ltd. (a

Business 52

Business Ownership Licensing Reporting 52

The IPKat

APRIL 5, 2023

In Neurim Pharmaceuticals (1991) Ltd and another company v Generics UK Ltd and another [2020] EWHC 3270 (Pat), Neurim was successful on all issues. Marcus Smith upheld his earlier finding that the patent was valid and therefore granted an injunction in Neurim v Generics (UK) Ltd (t/a Viatris ) [2022] EWHC 512 (Pat).

Reporting 73

Reporting Patent Patent Infringement Technology 73

SpicyIP

APRIL 17, 2023

At issue in Lt Overseas North America Inc & Anr. Case S ummaries Karnataka High Court sets aside the order of the Regional Director, Corporate Affairs, on failure to consider the interplay between Section 16 of Companies Act and Trademarks Act. Teva, Viatris win U.S. 2 (Lulu Mall). 2 (Lulu Mall).

Advertising 105

Advertising Advertising Confidentiality Trademark 105

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

Several other companies have also announced plans to pursue interchangeable status for biosimilar products. Consistent with this, as shown below in Table 2, numerous companies have publicly announced the submission and/or acceptance of new biosimilar BLAs. Semglee ® (Mylan (Viatris) / Biocon). December 17, 2021. Lucentis ®.

Litigation 52

Litigation Settlement Patent Marketing 52